AKT1

Across TCGA pan-cancer cohorts, AKT1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AKT1 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AKT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AKT1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where AKT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.247	0.805	.001	32	view →
HNSC	OS	Quartile	III,IV	0.578	0.946	.006	17	view →
CCRCC	DFS	Quartile	III,IV	1.000	0.443	.002	9	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	6	view →
PDAC	DFS	Quartile	III,IV	0.397	0.891	.035	5	view →
GBM	DFS	Quartile	All	0.605	0.830	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AKT1–LUAD (DFS)

Open the LUAD breakdown →